Canadian Know-How: Successfully Navigating a Centralized Framework for Oncology Clinical Trial Ethical Review
Now more than ever, time is of the essence when it comes to oncology clinical trial start-up and execution. The…
Why Does Your CRO’s Assignment Practice for CRAs Matter?
Monitoring the progress of the research represents a fundamental aspect of successful outcomes by ensuring that constraints to success are…
Does Your Monitoring Vendor Hold the Key to Improving the Quality of Your Database?
This article will discuss how involving your specialized CRO early in the database development phase can reduce the risk of…
Navigating Canadian Regulations for Oncology Clinical Research – Part I
Navigating Canadian Regulations for Oncology Clinical Research Your Questions Answered Part I Senior executives from oncology drug developers looking to…
Julie’s advice: Conducting oncology clinical research in Canada
Julie's advice: Conducting oncology clinical research in Canada Include Canada early in your drug development planning! Building relationships with key…
Clinical Trial Agreements no longer a bottleneck for study site activation
Ending the clinical trial agreement's sabotage of clinical trial startup Clinical trials are inherently complex, from pre-study startup through to…
‘5 step’ fail proof strategy to effective Clinical Trial Agreement Negotiations part 2
Continued from ‘5 step’ fail proof strategy to effective Clinical Trial Agreement Negotiation part 1 Nathan Currier, PhD, is Scimega's…
Oncology Clinical Operations in Canada
The nature and structure of our health care system in Canada results in patients being followed at the same center…
‘5 step’ fail proof strategy to effective Clinical Trial Agreement Negotiations part 1
Nathan Currier, PhD, is Scimega's Director of Oncology Strategy and Alliances. He brings a wealth of knowledge and excellent insight…